This poster was presented at the 30th annual Psych Congress, held Sept. 16-19, 2017, in New Orleans, Louisiana.
Traditional measures of MDD treatment response may miss meaningful changes for individual patients. A novel approach using a Goal Attainment Scale (GAS) Adapted for Depression (GAS-D) provides a framework to measure progress toward personalized treatment goals.
This Phase 4 open-label trial evaluated real-world effectiveness of the antidepressant vortioxetine on patients’ ability to achieve pre-identified treatment goals. The functional impact to patients and health outcomes results are also presented.
Patients with MDD, requiring a switch in antidepressant treatment, were given flexible-dose vortioxetine (10-20 mg) for 12 weeks. Successful attainment of pre-identified goals (primary outcome) was demonstrated by a GAS-D score of ≥50 at week 12.
Assessments of quality of life/life satisfaction (Q-LES-Q), well-being (WHO-5), workplace functioning (LEAPS), and healthcare resource utilization were completed.
Approximately 86% of patients (106/123) completed treatment—82.8% women, 69.2% white, mean age 45 years. For the primary endpoint, 57.8% of patients achieved a GAS-D score of ≥50 at week 12. Significant improvements (p<0.001) from baseline were noted at weeks 6 and 12 for WHO-5 and at week 12 for LEAPS (mean decrease, 5.7 points), Q-LES-Q total (mean increase, 1.13 points), and Q-LES-Q subscale scores assessing physical health/activity, feelings, work, household duties, leisure activities, social relations, and general activities. No significant increases in number of healthcare provider visits, hospitalizations, or sick days were observed.
A substantial proportion of vortioxetine-treated patients achieved their personalized treatment goals at week 12. Functional recovery indicators showed significant improvement without an increase in resource utilization.
Clinical outcomes are presented in a separate abstract.